Zealand Pharma A/S (OTCMKTS:ZLDPF) Downgraded to Hold Rating by Berenberg Bank

Berenberg Bank cut shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) from a strong-buy rating to a hold rating in a report published on Wednesday morning,Zacks.com reports.

Several other analysts have also issued reports on ZLDPF. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. BNP Paribas Exane lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Three research analysts have rated the stock with a Strong Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Zealand Pharma A/S has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $45.01 on Wednesday. The company’s 50 day moving average is $47.90 and its 200-day moving average is $57.22. Zealand Pharma A/S has a 12-month low of $35.93 and a 12-month high of $83.12. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a market cap of $3.22 billion, a P/E ratio of 3.34 and a beta of 0.86.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The company had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. Sell-side analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.